MXPA00006741A - Topical cosmetic product containing benzaldoxims - Google Patents

Abstract

The benzaldoxims of the present invention comprise at least a Hydrozoo or alkoxy aromatic group, which are active compounds in topical agents, cosmetic compositions, especially in skin clearing compositions.

Description

AGENTS FOR SKIN RINSE CONTAINING BENZALDOXIMAS Field of the invention. The invention relates to topical agents, cosmetics, especially to skin lightening agents, which contain benzaldoximes with at least one hydroxy or aromatic alkoxy group, for cosmetic or dermatological applications. Description of the prior art. The skin lightening active substances intervene, in some way, in the metabolism or in the catabolism of melanin. The melanins colored as a rule from brown to black are formed in the melanocytes of the skin, are transferred to the keratinocytes and cause the coloring of the skin or hair. The brown-black eumelanins are formed in mammals, mainly from the hydroxy-substituted aromatic amino acids such as L-tyrosine and L-DOPA, the yellow pheomelanins up to red are also formed from the sulfur-containing molecules (Cosmetics &Toiletries 1996, 111 (5), 43-51). L-3,4-dihydroxyphenylalanine (L-DOPA) is formed from L-tyrosine by means of the key enzyme, which contains copper, constituted by tyrosinase, which, in turn, is oxidized again by tyrosinase to through the dopaquinone, colored red-brown, to give melanin. A comparison between tyrosinases from plants, fungi and mammals shows that the mechanism and specificity of the substrate is comparable in all the tyrosinases tested. If melanocytes, which are melanin-forming, are not homogeneously distributed on human skin for any reason, pigment spots appear that are either lighter or darker than the skin area.

REF.121133 surrounding. To eliminate this problem, skin lightening agents are offered on the market, which help to match, at least in part, such pigment spots. There is also a need, for many human beings, to clarify the color of their dark skin by nature. This requires safe and effective skin lightening agents. Many skin rinse agents contain much less potent tyrosinase inhibitors. Commercially available skin rinsing agents are used, in particular, hydroquinone, hydroquinone derivatives such as, for example, arbutin, vitamin C, ascorbic acid derivatives such as, for example, ascorbyl palmitate, kojic acid and acid derivatives. kojic such as for example the dipalmitate of kojic acid. One of the most frequently used skin rinsing agents is hydroquinone. The substance, however, has a cytotoxic effect against the melanocytes and can damage the skin, therefore such preparations are no longer allowed, for example in Japan or South Africa, for cosmetic applications. In addition, hydroquinone is very sensitive to oxidation and can only be stabilized with difficulties in cosmetic formulations. Vitamin C and ascorbic acid derivatives have only an insufficient effect on the skin. Furthermore, they do not directly act as inhibitors of the? Nase shot but reduce the colored intermediate product of melanin biosynthesis. Kojic acid (5-hydroxy-2-hydroxymethyl-4-pyranone) is a tyrosinase inhibitor, which inhibits the catalytic effect of the enzyme by chelating the copper atom; It is used in commercial skin lightening agents. The substance is formed primarily in Aspergillus cultures and can only be isolated from them in small amounts. Detailed description of the invention. The task of the present invention was to find inexpensive, easily obtainable, highly effective, tyrosinase inhibitors which could be used as active agents for skin rinsing agents.

The invention relates to toxic, cosmetic agents containing benzaldoximes of the general formula their geometric isomers or mixtures of these isomers, where R \ R5, independently of each other, mean hydrogen atoms or alkyl groups with 1 to 4 carbon atoms, R2, R3, R4, independently of each other, can mean hydrogen atoms, groups hydroxy, alkyl groups with 1 to 4 carbon atoms or groups -O-R7, where R7 can mean an alkyl group with 1 to 4 carbon atoms or an arylalkyl group with 7 to 10 carbon atoms, with the proviso that minus one of the radicals R2 to R4 signifies a hydroxy group or a group -OR7, where R7 has the meaning indicated above, and R6 signifies a hydrogen atom, an alkyl or alkenyl group with 1 to 12 carbon atoms or an aryl group or arylalkyl, optionally substituted, with 7 to 10 carbon atoms or a heteroaryl or "" heteroarylalkyl group, optionally substituted with 2 to 10 carbon atoms, containing one or more heteroatoms of the group formed by sulfur, nitrogen or oxygen. Preferred are topical, cosmetic agents containing benzaldoximes of the general formula their geometric isomers or mixtures of these isomers, where R1 and R5 signify hydrogen, and R2, R3 and R4, independently of each other, can mean hydrogen atoms, hydroxy groups, alkyl groups with 1 to 4 carbon atoms or groups -O- R7, wherein R7 may represent an alkyl group with 1 to 4 carbon atoms or an arylalkyl group with 7 to 10 carbon atoms, with the proviso that at least one of the radicals R2 to R4 means a hydroxy group or a group - O-R7, where R7 has the meaning indicated above, and R6 signifies a hydrogen atom, an alkyl or alkenyl group with 1 to 12 carbon atoms or an arylalkyl group with 7 to 10 carbon atoms, optionally substituted. Particularly preferred are cosmetic topical agents containing benzaldoximes, selected from the group comprising, for example, 4-hydroxybenzaldoxime 3,4,5-Trihydroxybenzaldoxime 3-hydroxy-4-methoxybenzaldoxime-O-ethylxime 3-ethoxy-4-hydroxybenzaldehyde-O -ethyl oxime 3,4-Dihydroxybenzaldoxime 3-Hydroxy-4-methoxybenzaldoxime 4-Hydroxy-3-methoxybenzaldehyde-O-ethyl oxime 3,4-Dihydroxybenzaldehyde-O- (4-methylbenzyl) oxime 3-Ethoxoxy-4-hydroxybenzaldoxime 4-Hydroxy -3-methoxybenzaldoxime 3,4-Dihydroxybenzaldehyde-O-ethyl-oxime without this list being limiting. It has now been found, surprisingly, that benzaldoxime, contained in the topical, cosmetic agents according to the invention, are particularly potent tyrosine inhibitors. Especially many of the benzaldoxime according to the invention are fundamentally more effective than kojic acid. Therefore they can be used as active ingredients in cosmetic or dermatological agents for rinsing the skin. The topical, cosmetic agents according to the invention, especially the skin-lightening agents, which contain the benzaldoximes are prepared according to customary methods, known per se, in such a way that one or more of the benzaldoxime according to the invention are incorporated. in cosmetic or dermatological formulations, which are composed in the usual way and which can be used, in addition to the skin lightening effect, also for the treatment, care and cleaning of the skin or hair and as makeup products in decorative cosmetics . The present invention thus also relates to topical, cosmetic agents, especially cosmetic and dermatological skin rinse agents, which comprise the benzaldoximes according to the invention in an active amount in addition to other components of the composition, customary at the rest. These contain from 0.01% by weight to 30% by weight, preferably from 0.01 to 20% by weight, in particular from 0.01 to 5% by weight, based on the total weight of the formulation, of the benzaldoximes according to invention and can be presented in this case as "water in oil" emulsions, "oil in water", "water in oil in water" or "oil in water in oil", as microemulsions, as gels, as solutions for example in oils, alcohols or silicone oils, as pens , by way of soaps, by way of aerosols, sprays or also foams. Other customary auxiliaries and cosmetic additives may be present in amounts of 5 to 99% by weight, preferably 10 to 80% by weight, based on the total weight of the formulation. In addition, the formulations can have water in an amount of up to 99.99% by weight, preferably from 5 to 80% by weight, based on the total weight of the formulation. The benzaldoximes, contained in the skin rinsing agents according to the invention, are partially known. Benzaldoximes according to the invention, known, are described, for example, in the Chem. Ber. 1883, 16, 1780 to 1787, Chem. Ber. 1941, 74, 79, 87 and 89, Chem. Ber. 1922, 55, 920 to 929, in Chem. Ber. 1922, 55, 2357 to 2372 and in Liebigs Ann. 1936, 526, 277-294. No indication has been given about an effect as inhibitors of tyrosinase or its use in cosmetic and / or dermatological preparations. The benzaldoximes according to the invention, contained in the skin-lightening agents, are prepared, insofar as they are not yet known, according to methods known to those skilled in the art by reaction of the corresponding benzaldehyde with the corresponding hydroxylamines or their salts in a solvent, preferably in water, in an aliphatic alcohol with 1 to 4 carbon atoms or in a mixture of the solvents, with an auxiliary base, preferably sodium hydroxide or sodium acetate, at 0 ° C to 120 °. C, preferably at 20 ° C to 100 ° C, if necessary neutralized with a mineral acid and purified by the usual procedures, preferably by crystallization. As benzaldehydes, preference will be given to 4-hydroxybenzaldehyde, 3,4-trihydroxybenzaldehyde (galloaldehyde), 4-methoxy-3-hydroxybenzaldehyde (isovaniline), 3-ethoxy-4-hydroxybenzaldehyde (ethyl vanillin), 3,4-dihydroxybenzaldehyde. -hido (protocatechualdehyde) or 4-hydroxy-3-methoxybenzaldehyde (vanillin). The hydroxylamines used are preferably hydroxylamine, O-ethylhydroxylamine or O-4-methylbenzylhydroxylamine or the salts of the hydroxylamines mentioned. The topical, cosmetic agents according to the invention, especially the skin-lightening agents, may contain auxiliary products and cosmetic additives, such as those usually used in such preparations, for example sun-protecting agents (for example filtering substances). of organic or inorganic light, preferably micropigments), preservatives, bactericides, fungicides, virucides, refreshing active ingredients, plant extracts, active products of inflammation, products accelerating the healing of wounds (for example chitin or chitosan and its derivatives) , film-forming substances (for example polyvinylpyrrolidone or chitosan or its derivatives), usual antioxidants, vitamins (for example vitamin C and derivatives, tocopherols and derivatives, vitamin A and derivatives), 2-hydroxycarboxylic acids (for example citric acid, malic acid) , L-, D- or dl-lactic acid), agents for rinsing the skin (p for example kojic acid, hydroquinone or arbutin), skin coloring agents (for example walnut extracts or dihydroxyacetone), perfumes, substances to prevent frothing, dyes, pigments, having a coloring effect, thickeners, substan surfactants, emulsifiers, plasticizers, humectants and / or moisture preservatives (for example glycerin or urea), fats, oils, unsaturated fatty acids or their derivatives (for example linoleic acid, α-linoleic acid, acid? -linolenic or arachidonic acid and their respective natural or synthetic esters), waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam inhibitors, electrolytes, organic solvents, silicone derivatives or chelating agents (for example ethyl-iodide-tetra-acetic acid and derivatives). The amounts to be used, respectively, of auxiliary products and of cosmetic or dermatological additives and of perfume can be easily determined by the person skilled in the art according to the type of the corresponding product by means of simple preliminary tests. Preferably, the skin rinsing agents according to the invention, which contain the benzaldoximes according to the invention, can also contain other active ingredients for rinsing the skin. Especially skin cleansing agents may also contain kojic acid, kojic acid derivatives, ascorbic acid, ascorbic acid derivatives, hydroquinone, hydroquinone derivatives, sulfur-containing molecules such as for example glutathione or cysteine or other synthetic active products. or natural for rinsing the skin, the latter also being able to be used in the form of an extract of plants, such as, for example, aguavilla extract and rice extract. The amounts of the other active ingredients, mentioned above in an exemplary manner, for rinsing the skin (one or more compounds), which are not identical to the benzaldoximes contained in the skin rinsing agents according to the invention, can can be found in the rinse agents according to the invention in a proportion of 0.01 to 30% by weight, preferably 0.01 to 20% by weight, particularly preferably 0.01 to 5% by weight, based on the total weight of the preparation. However, the skin rinsing agents according to the invention, which contain the benzaldoximes according to the invention, can also contain, in addition, UVA and / or UVB filtering substances, the total amount of the filtering substances being the proportion of 0.1 to 30% by weight, preferably 0.5 to 10% by weight, based on the total weight of the preparation, obtaining, for example, sun-protecting agents for the skin and the neck. Examples of UV filtering substances which can be used are 3-benzylidenecamphor derivatives (for example 3- (4-methylbenzylidene) dl-camphor), aminobenzoic acid derivatives (for example 4- (N, N-dimethylamino) benzoate). of 2-ethylhexyl or methylanthranilate), 4-methoxycinnamates (for example 2-ethylhexyl-p-methoxycinnamate or isoamyl-p-methoxycinnamate), benzophenone (for example 2-hydroxy-4-methoxybenzophenone), UV filters mono or polysulphonates [for example 2-phenylben-cimidazole-5-sulfonic acid, sulisobenzones or l, 4-bis (benzimidazolyl) -benzole-4,4 ', 6,6'-tetrasulfonic acid or 3,3' - ( 1, 4-phenylenedimethylidene) -bis- (7,7-dimethyl-2-oxo-bicyclo- [2,2, 1] heptan-1-methanesulfonic acid) and its salts], salicylate (for example 2-salicylate) ethylhexyl or homomethyl salicylate), triazines. { for example 2,4-bis- [4- (2-ethylhexyloxy) -2-hydroxyphenyl] -6- (4-methoxyphenyl) -1,3,5-triazine, 4,4 '- ([6 - ([ (1, 1 -dimethylethyl) -aminocar-bonyl] phenylamino) -l, 3,5-triazin-2,4-diyl] dimino) bis-benzoate (2-ethylhexyl))} , 2-cyanopropenoic acid derivatives (for example 2-ethylhexyl-2-cyano-3,3-diphenyl-2-propenoate), dibenzoyl derivatives (for example 4-tert-butyl-4'-p-ethoxydiben-zoylmethane), UV filters bonded with polymers (for example polymer of N- [2- (or 4) - (2-oxo-3-borniIiden) methyI] -benzylacrylamide) or pigments (for example titanium dioxides, zirconium dioxides, iron oxides, silicon dioxides, manganese oxides, aluminum oxides, cerium oxides or zinc oxides). The lipid phase in the topical, cosmetic agents according to the invention can be chosen advantageously from the following group of substances: mineral oils (advantageously paraffin oil), mineral waxes, hydrocarbons (advantageously squalane or squalene), synthetic or semi-synthetic triglyceride oils (for example triglycerides or caprylic acid or caprylic acid), natural oils, for example castor oil, olive oil, sunflower oil, soybean oil , peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, borage seed oil and the like, natural sterols (for example, jojoba oil), synthetic sterols, ( preferably esters of alkanecarboxylic acids with 3 to 30 carbon atoms, saturated and / or unsaturated, linear and / or branched, with alcohols with 3 to 30 carbon atoms saturated and / or unsaturated, linear and / or branched and esters of carboxylic acids aromatics with alcohols with 3 to 30 carbon atoms saturated / unsaturated, linear and / or branched, especially chosen from the group consisting of myristate of isopropyl, isopropyl stearate, isopropyl palmitate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl laurate, isooctyl stearate, isononyl stearate, isonolyl isononanoate, 2-ethylhexyl palmitate. 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate as well as natural or synthetic mixtures of such esters), fats, waxes and other bodies natural and synthetic fatty acids, preferably esters of fatty alcohols with alcohols with a low number of carbon atoms (for example with isopropanol, propylene glycol or glycerin) or esters of fatty alcohols with alkanoic acids with a low number of carbon atoms or with fatty acids , alkyl benzoate (for example mixtures of n-dodecyl benzoate, n-tridecyl, n-tetradecyl and n-pentadecyl), as well as cyclic or linear silicone oils (such as for example dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes, as well as mixed ones). The aqueous phase of the cosmetic topical agents according to the invention contains, if appropriate, alcohols, dioxopolol, with a low number of carbon atoms, as well as their ethers, preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl - or - monobutyl ether, propylene glycol monomethyl ether, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products, furthermore alcohols with a low number of carbon atoms, for example ethanol, isopropanol, 1,2-propanediol, glycerol, - or β-hydroxy acids, preferably lactic acid, citric acid or salicylic acid, furthermore emulsifiers, which may advantageously be selected from the group consisting of ionic, nonionic, polymeric, phosphate-containing and zwitterionic emulsifiers, and especially one or more thickeners, which can or can be chosen from the group consisting of silicon dioxide, aluminum silicates, such as for example bentonite, polysaccharides or their derivatives, for example ialuronic acid, guar seed flour, xanthan gum, hydroxypropylmethylcellulose or alulose derivatives, particularly advantageously from the group consisting of polyacrylates, preferably a polyacrylate of the group of so-called carbopolos , respectively individually or in combination or from the group of polyurethanes. The topical, cosmetic agents according to the invention, especially the skin-lightening agents, which contain the benzaldoximes according to the invention will be used for cosmetic products in a customary manner on the skin and / or on the hair in sufficient quantities. Examples The following examples will explain the present invention without limiting it in any way.

Example 1: Emulsion "oil in water" Part A was mixed and heated to 80 ° C. Part B was mixed and heated to 90 ° C and added to part A under stirring. For part C carbopol was carefully dispersed in water and neutralized with sodium hydroxide solution (pH 6.9). Part C was then added, at 60 ° C, to the mixture formed by parts A and B. Part D was added to the mixture formed by parts A, B and C, at room temperature. Example 2: "Water in oil" emulsion with broad spectrum protection against UVA / B.

For part A all substances were heated, with the exception of zinc oxide, at 85 ° C and the zinc oxide was carefully dispersed in the mixture. The components of part B were mixed, heated to 85 ° C and added to Part A under agitation. Part A and Part C were added to the mixture formed by parts A and then the mixture was homogenized with a dispersion. Example 3: "Oil in water" emulsion with broad spectrum protection against UVA / B.

For part A, all substances were mixed with the exception of titanium dioxide and heated to 85 ° C; The titanium dioxide was carefully dispersed in the mixture. For part B all substances were mixed with the exception of Veegum and Natrosol, heated to 90 ° C, Natrosol and Veegum were dispersed and the mixture was added, under agitation, to part A. It was added to the mixture formed by parts A and B, part C and then the mixture was homogenized with a dispersion device. Example 4: "Oil in water" emulsion with broad spectrum protection against UVA / B.

Part A was heated to 85 ° C. The Carbopol and Keltrol were cold dispersed in the remaining components, the mixture was heated to 85 ° C and added to panel A. Part C was added immediately, at 80 ° C, to the mixture formed by parts A and B and homogenized for 5 minutes with a dispersing device. Part D was then added at room temperature and the mixture was homogenized with a dispersion device. Synthesis routine of benzaldoximes. The benzaldehyde (87 mmoles) was dissolved in 45 ml of water at 40 ° C. A solution of the corresponding hydroxylamine chloride (90 mmol) and sodium acetate (87 mmol) in 20 ml of water was added and the reaction mixture was stirred at about 80 ° C for 2 hours under nitrogen. The mixture was extracted, after cooling, with 200 ml of tert-butyl methyl ether, the organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate, filtered off and the filtrate was concentrated by evaporation in vacuo. to dryness The crystalline residue was recrystallized, if appropriate.

Table 1.

Experiment. The activity to inhibit the tyrosinase of test compounds 1 to 11 was compared with that of kojic acid in the following manner: The tyrosinase enzyme, extracted from fungi, was purchased from the Sigma-Aldrich Company. Tyrosinase (2,000 units / mg) was dissolved in phosphate buffer (pH 6.8, 0.067 moles / liter) to a concentration of 120 units / ml and 100 μl of this tyrosinase solution was placed in a cavity of a polystyrene microtiter plate. 25 μl of phosphate buffer (pH 6.8, 0.067 mol / liter) and 75 μl of test compound 1 to 11, stepwise diluted, or of kojic acid were added. The mixtures formed were incubated for 10 minutes at 37 ° C. Phosphate buffer (pH 6.8, 0.067 moles / liter) was used for the dilution of the test compounds. As a control, phosphate buffer (pH 6.8, 0.067 moles / liter) was used. 100 μl of a 0.03% solution of the substrate L-DOPA in phosphate buffer (pH 6.8, 0.067 mol / liter) was added and the absorption (A) was measured at 475 nm with the help of a photometer after 3 minutes incubation at 37 ° C. The residual activities of tyrosinase in the presence of examples 1 to 11 or of kojic acid were calculated according to the following equation: Tyrosinase reactivity (%) = A composed of enuyo / Acomroi) x 100.

From the residual activities (%) of the tyrosinase in a series of dilutions of the test compounds, the HK_o was calculated for each test compound. This is the concentration of a test compound at which tyrosinase is inhibited by 50%. Table 2 Kojic acid 22 Test compound 1 25 Test compound 2 Test compound 3 18 Test compound 4 14 Test compound 5 18 Test compound 6 4,6 Test compound 7 4,2 Test compound 8 3 Test compound 9 3.5 Test compound 10 2.3 Test compound 11 0.3. It is noted that in relation to this date, the best method known to the applicant, to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (1)

1. ETVINDICATIONS Being unleashed as above, you will see mcopüp_tpiedadba_píep ^ rsMiYfraránnes: l.-Agertestópioos, cosmetics, quecxiptiennenbenzd ia ± asbíorniilagen ^ its geometric isomers or mixtures of these isomers, where R1, R5, ind-peadEptanepiB eme s? do they mean hydrogen atoms or alkano groups with 1 to 4 carbon atoms, R2, R3, R, independent of each other? can zapifkar hydrogen atoms, hydroxy guipas, albibcon groups 1 to 4 amassy? txM? o? i?)? sO-R7, where R7puedb mean a group to fo with 1 to 4 caubone atoms or an arflalquflo guipo with 7 to 10 atan of caibono, with confection of at least one of the residues R2 to R signifies an Hdraxi group or a group -OR7 where R7 has the meaning arteriormepts indicated, and R6 signifies a hydrogen atom, a group at jirifo or alkenib ccn 1 up to 12 carbon atoms or a aryl or arylaltrib group, optionally substituted, with 7 to 10 carbon atoms or a group of haeraarib or hydrochloride, optionally substituted with 2 to 10 carbon atoms, containing one or more heteroatoms from the group ft > pnadopcrazu__e ^? _i_p_genouox ^ eno. 2.- Topical agents, cosmetics, containing benzaldoximes of the general formula their geometric isomers or mixtures of these isomers, where R1 and R5 mean hydrogen, and R \ R3 and R4, independently of each other, can mean hydrogen atoms, hydroxy groups, alkyl groups with 1 to 4 carbon atoms or groups -O- R7, wherein R7 may represent an alkyl group with 1 to 4 carbon atoms or an arylalkyl group with 7 to 10 carbon atoms, with the proviso that at least one of the radicals R2 to R4 means a hydroxy group or a group - O-R7, where R7 has the meaning indicated above, and R6 represents a hydrogen atom, an alkyl or alkenyl group with 1 to 12 carbon atoms or an arylalkyl group with 7 to 10 carbon atoms, optionally substituted. 3.- Topical agents, cosmetics, containing 4-Hydroxybenzaldoxime 3,4,5-Trihydroxybenzaldoxime 3-Hydroxy-4-methoxybenzaldoxime-O-ethyl oxime 3-ethoxy-4-hydroxybenzaldehyde-O-ethylhexime 3,4-Dihydroxybenzaldoxime 3-Hydroxy -4-methoxybenzaldoxime 4-Hydroxy-3-methoxybenzaldehyde-O-ethylimene 3,4-Dihydroxybenzaldehyde-O- (4-methylbenzyl) oxime 3-Etoxoi-4-hydroxybenzaldoxime 4-H idroxy-3-methoxybenzaldoxime 3,4-Dihydroxybenzaldehyde -O-ethylxime. 4. Topical cosmetics agents according to claims 1 to 3, containing from 0.01% by weight to 30% by weight, preferably from 0.01 to 20% by weight, especially however from 0.01% by weight. weight up to 5% by weight, based on the total weight of the formulation, of the benzaldoximes of the general formula I. 5. Use of the topical, cosmetic agents according to claims 1 to 4, as agents for rinsing the skin . 6. Use of the benzaldoximes according to claims 1 to 3, in cosmetic preparations. 1. Use of the benzaldoximes according to claims 1 to 3 in dermatological preparations. 8. Use of the benzaldoximes according to claims 3, in agents for protection against the sun. 9. Use of benzaldoximes according to claims 1 to 3 in hair care product. 10. Use of the benzaldoximes according to claims 1 to 3, in anti-aging products of the skin.